CD19 and precursor B-cell acute lymphoblastic leukemia: Although Mueller et al. [39] reported that cellular and humoral responses to murine CD19 CAR-T did not impact therapeutic efficacy and safety in B-ALL, their study was based on CAR-naïve cohorts.